Elaine Weidenhammer

In July 2023, we changed our name from AACC (short for the American Association for Clinical Chemistry) to the Association for Diagnostics & Laboratory Medicine (ADLM). The following page was written prior to this rebranding and contains mentions of the association’s old name. It may contain other out-of-date information as well.

2003 Sigi Ziering Award for Outstanding Contribution for a Publication in the Journal Clinical Chemistry

Elaine Weidenhammer, PhD, is associate director of corporate development at Nanogen (San Diego, CA), a biotechnology company that develops electronic microarrays for use in clinical diagnostics.

She joined Nanogen as a research scientist in 1998 and spent the next 4 years developing gene expression and genotyping applications on the NanoChip microarray.

She was involved in the development of novel methodologies for analyzing concentrations of multiple mRNA transcripts over multiple time points on a single microarray. This work produced a recently granted patent, in addition to the winning article, “Multiplexed, Targeted Gene Expression Profiling and Genetic Analysis on Electronic Microarrays”. Her co-authors were Brenda F. Kahl, Ling Wang, Larry Wang, Melanie Duchon, Jo Ann Jackson, Matthew Slater, and Xiao Xu.

Dr. Weidenhammer recently made the transition from research and development to corporate development at Nanogen. In this role, she provides technical expertise for guiding Nanogen’s strategic development efforts, coordinates external research collaborations, and presents Nanogen’s technology at various workshops and scientific meetings.

She is active in the San Diego chapter of the Association for Women in Science, serving as chapter president for 3 years and co-chairing the organizing committee for the chapter’s Women in Bioscience Conference, a biannual event that draws more than 350 people.

Dr. Weidenhammer's award winning article can be read in its entirety at http://www.clinchem.org/cgi/content/full/48/11/1873